BioVoice News eMag April 2025 | Page 17

Major biologics facing patent expiration
S. No. Name
Company
Indication
Patent
Expiry
Sales
1 Keytruda( Pem brolizumab)
Merck Various cancers
2028 $ 25 billion
2
Opdivo( Nivolumab)
Bristol Myers
Squibb
Multiple Cancers
2026-27 $ 9.3 billion
3
Eylea( Aflibercept)
Regeneron /
Bayer
Macular degeneration
2025-26 $ 25 billion
4 Stelara( Ustekinumab) Johnson & Johnson
Macular degeneration
2023-24 $ 25 billion
5 Cimzia( Certolizumab Pegol)
UCB Crohn’ sdisease, rheumatoid arthritis
2024 $ 2.04 billion
6
Trulicity( Dulaglutide)
Eli Lilly
Type 2 Dia
betes
2023 $ 7.1 billion
7 Perjeta( Pertuzumab) Roche Breast Cancer 2025-26 $ 3.616 billion
8
Simponi( Golimumab)
Janssen
Biotech
Rheumatoid arthritis, psoriatic arthritis
2024 $ 576 million
9
Ilaris( Canakinumab)
Novartis
Systemic juvenile idiopathic arthritis
2022 $ 576 million
10 Blincyto( Blinatu momab)
Amgen
Systemic juvenile idiopathic arthritis
2025 $ 103 million
BIOVOICENEWS. COM 17